Charles River Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells
21 February 2024 - 12:08AM
Business Wire
The addition of ES cells and iPSCs will enhance
Charles River’s portfolio of powerful research tools supporting
acceleration of therapeutic development.
Charles River Laboratories International, Inc. (NYSE: CRL) today
announced that it has entered into an agreement with Pluristyx
Inc., a leading provider of tools, technologies, and services for
the development of cell therapies. The collaboration provides
Charles River with broad access to highly characterized and unique
stem cell lines, including high-quality embryonic stem (ES) cells
and induced pluripotent stem cells (iPSCs) as research tools to
support development of new therapeutics.
Pluristyx offers a unique product and technology platform in the
stem cell biology field for development of new therapies while
reducing timelines and downstream costs. Through the agreement,
Charles River will distribute Pluristyx’s wild-type and genetically
engineered iPSCs as well as their comprehensive portfolio of normal
and disease state ES cell lines. All of Pluristyx’s pluripotent
cell lines are produced under full donor consent and the ES cell
lines are registered and approved by the U.S. National Institutes
of Health (NIH) making them eligible for use in NIH-funded
research. Pluristyx’s iPSC panCELLa™ platform includes the
proprietary FailSafe® safety-switch technology enabling the
development of safer, next-generation cell therapies.
Under the terms of the agreement, Charles River will distribute
a broad catalog of Pluristyx’s ES and iPS cell lines for research
use and will exclusively offer specific pluripotent stem cell lines
derived under Good Tissue Practice to support a path to the clinic.
The addition of Pluristyx’s offerings complements Charles River’s
expansive portfolio of high-quality human cellular materials.
Shaping the Future of Drug and Therapeutic
Development
ES and iPS cells provide a valuable tool for researchers to gain
access to various types of specialized and differentiated cells
that are otherwise inaccessible to study disease onset and
progression and to develop a multitude of effective therapies. With
its expanded portfolio of ES and iPS cell lines, Charles River
enhances its position as a global leader in supplying critical
human-derived biomaterials, including a wide range of immune cells
and hematopoietic stem cells from both healthy donors and patients
to drive advancements in stem cell biology, disease remodeling,
toxicity studies, developmental biology, regenerative medicine,
drug discovery, and cell therapy development.
Charles River is committed to leading the industry in
identifying technologies and supporting efforts by global
regulatory bodies to advance solutions that reduce the impact on in
vivo research models through its 4Rs mission. The development of
complex in vitro models using human-derived cells is one of many
critical steps in revolutionizing therapeutic research and
development. The alliance with Pluristyx provides Charles River
clients access to research tools for advancing in vitro
translational cell-based assays for drug discovery.
Approved Quotes
- “We are thrilled to integrate Pluristyx into our robust
portfolio of human cell products and services. This alliance
provides our clients with access to high quality research tools,
adding considerable value and helping to develop safe and effective
therapies to patients across the globe.” - Birgit Girshick,
Executive Vice President and Chief Operating Officer, Charles
River
- “We are honored to work with Charles River as a worldwide
distributor of our pluripotent stem cells, including our
genetically modified iPSCs that provide an accelerated path to the
clinic with development of safer cell therapies. Through this
agreement, we can continue our mission to rapidly advance
development of next generation therapies.” - Benjamin Fryer, PhD,
Chief Executive Officer, Pluristyx
About Pluristyx
Pluristyx, through its panCELLa™ platform, offers a portfolio of
unique iPSC-based technologies, proprietary genetic engineering,
and related tool-products and services to provide end-to-end client
support throughout the products’ lifecycle. Pluristyx is fast
becoming the leading provider of gene-edited iPSC and cell therapy
solutions, accelerating customers’ path to clinic, and providing
the best and fastest route to commercialization of cell-based
therapeutic products. For more information on Pluristyx, visit
www.pluristyx.com.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development, and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240220481133/en/
Charles River Investor Contact: Todd Spencer Corporate
Vice President, Investor Relations 781.222.6455
todd.spencer@crl.com
Charles River Media Contact: Amy Cianciaruso Corporate
Vice President, Chief Communications Officer 781.222.6168
amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Sep 2023 to Sep 2024